Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Early Phase 1 Clinical Trial To Evaluate the Safety and Efficacy of Human CD19-CD22 Targeted T Cells Injection for Subjects With Central Nervous System Involvement of Refractory/Relapsed B Cell Malignancies

NCT05651178 is registered in ClinicalTrials.gov with Hrain Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05651178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05651178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Early Phase 1 Clinical Trial To Evaluate the Safety and Efficacy of Human CD19-CD22 Targeted T Cells Injection for Subjects With Central Nervous System Involvement of Refractory/Relapsed B Cell Malignancies
Lead sponsor
Hrain Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 12, 2022
Completion date
May 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system lymphoma